Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG PEN versus HUMALOG TEMPO PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG PEN versus HUMALOG TEMPO PEN.
HUMALOG PEN vs HUMALOG TEMPO PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that binds to the insulin receptor, activating tyrosine kinase activity and downstream signaling pathways (e.g., PI3K/Akt) to promote glucose uptake in skeletal muscle and adipose tissue, inhibit hepatic gluconeogenesis, and regulate lipid and protein metabolism.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Subcutaneously 0.5–1 unit/kg/day divided into multiple doses (usually 3 or more), administered 15 minutes before or immediately after meals.
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
None Documented
None Documented
Approximately 0.5-1 hour (rapid; subcutaneous absorption rate-limited).
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
Renal: 60-80% of dose excreted as metabolites; remainder hepatobiliary and fecal.
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Category C
Category C
Insulin Analog
Insulin Analog